United States · Pharmaceuticals
Pharmaceuticals
Biotechnology
Healthcare
Nuvation Bio is a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, and Shanghai.
2018
Founded
Pharmaceuticals
Industry
United States
Location
1,721,180
Ranking
300 employees
Size

Get full access to view complete information
